NEW YORK (GenomeWeb) – Agilent Technologies reported after the close of the market Tuesday that its revenues for the first quarter grew 4 percent year over year.

For the three months ended Jan. 31, Agilent recorded $1.07 billion in revenues, up from $1.03 billion in Q1 2016 and beating the average Wall Street estimate of $1.05 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.